NCT01563926

Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency

An Open, Multi-Centre Trial Evaluating Acceptance of the New Liquid Growth Hormone Formulation - Norditropin Simplexx™ in Children With GH Deficiency

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 168 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This trial is conducted in Asia. The aim of this trial is to evaluate the new liquid somatropin formulation in children with growth hormone deficiency.

Conditions

• Growth Hormone Disorder
• Growth Hormone Deficiency in Children
• Genetic Disorder
• Turner Syndrome

Interventions

Type	Name	Description
DRUG	somatropin	Dosed by individual needs as judged by the Investigator (trial physician). Injected subcutaneously (s.c./under the skin)

Timeline

• Start date: 2000-10-23
• Primary completion: 2002-10-10
• Completion: 2002-10-10
• First posted: 2012-03-27
• Last updated: 2017-02-27

Locations

6 sites across 1 country: Israel